Mesotherapy for Pain (Intradermotherapy)

What mesotherapy is

Mesotherapy — also called intradermotherapy — consists of multiple superficial intradermal injections of small volumes (0.1 to 0.3 mL per point) of pharmacologic solutions applied in a multifocal pattern over a painful area. Formulations vary widely between practitioners and may combine local anesthetics (lidocaine, procaine), nonsteroidal anti-inflammatory drugs at diluted concentrations, vasodilators, B-complex vitamins (especially B12), and other components. There is no established standardization.

The technique differs from other injectable modalities in important respects. In trigger point injection, the needle targets a specific palpable taut band (point-by-point approach); in perineural or articular blocks, the substance is deposited in a defined deep plane based on the anatomy of the target. Mesotherapy, by contrast, distributes multiple superficial microinjections in a regular grid over the entire affected area, without a precise anatomical target in a deep plane.

The technique was described by Michel Pistor in France in 1958 and later systematized by the Société Française de Mésotherapie. Its clinical diffusion is historically concentrated in France, Italy, and some Latin American countries. In Anglo-American evidence-based medicine — and in international pain medicine guidelines (NICE, IASP, ASA) — mesotherapy has neither tradition nor formal endorsement, which reflects the scarcity of quality studies and robust systematic reviews.

Proposed mechanism

The mechanisms attributed to mesotherapy are largely hypothetical. The available literature proposes at least four lines, none fully established in good-quality human studies: a component of local gate control through mechanical stimulation of the dermis, which is rich in nerve endings; slow pharmacologic absorption, with the drug remaining deposited in a superficial plane and releasing gradually; a putative somato-visceral reflex effect mediated by segmental cutaneous innervation; and a local tissue stimulus from the microtrauma of the multiple punctures, with low-grade inflammatory modulation.

The limits of these models deserve to be made explicit: the proposed mechanisms remain largely theoretical. Mechanism studies in humans are scarce, based on small series, with significant heterogeneity in formulations and outcomes evaluated. The frequent analogy with mechanisms of acupuncture or trigger point injection does not replace dedicated evidence — each technique requires specific validation of its biological effect, and mesotherapy has not yet accumulated that validation.

A meaningful share of the observed clinical effect may also be explained by nonspecific components: placebo effect, with magnitude estimated at 30-40% in injectable interventions for pain; natural history of the condition treated, since many painful syndromes improve spontaneously over the course of weeks; and statistical regression to the mean, due to selection of patients at moments of high symptomatic intensity. These factors are particularly relevant in studies without a sham control and with short follow-up.

Scientific evidence

An honest reading of the literature on mesotherapy in pain requires distinguishing two planes: the volume of clinical reports and descriptive series, which is sizeable, and the volume of methodologically adequate randomized clinical trials (RCTs), which is small. This asymmetry is the central reason why the technique, despite decades of use, has not earned endorsement in international pain medicine guidelines.

The review by Costantino, Marangio & Coruzzi (Rheumatology International, 2011) — one of the most cited syntheses — compared mesotherapy with systemic therapy in musculoskeletal conditions and concluded that the evidence was weak, with small studies, frequently open-label, heterogeneous in protocol and outcomes. To date, there is no specific Cochrane review dedicated to mesotherapy in pain — a methodological gap that, in itself, reflects the marginal position of the technique in evidence-based medicine.

In terms of guidelines, the absence is consistent: NICE (United Kingdom) does not mention mesotherapy in its recommendations for primary chronic pain or low back pain; the IASP (International Association for the Study of Pain) does not list it among modalities with formal recommendation; the American Society of Anesthesiologists (ASA) does not include mesotherapy in pain management protocols. This non-inclusion is not an oversight: it reflects the insufficiency of data to support a formal recommendation.

In low back pain, neck pain, and myofascial pain syndrome, the options with more robust evidence — structured prescribed exercise, dry and wet trigger point needling, medical acupuncture, oral analgesics in short courses when indicated, cognitive behavioral therapy for chronic pain — should be prioritized before considering mesotherapy. The technique has no place as a first choice in any of the well-established painful conditions.

Indications

Mesotherapy should not be positioned as a first option in any of the most common painful conditions. When it is considered, that happens in specific scenarios and always with realistic expectations about the available evidence — typically as an adjunct, in selected contexts, and after an honest discussion with the patient about the current scientific basis. What follows are not strong indications, but situations in which the technique can be considered, in the absence of better options for the specific case.

How it is done and what to expect

The session is done in a medical office, with the patient positioned to expose the area to be treated. After skin antisepsis, the physician performs multiple superficial intradermal microinjections using a fine needle (30G), with volumes per point between 0.1 and 0.3 mL, distributed in a regular grid pattern over the painful region. The number of points per session varies according to the extent of the area (it can reach dozens of microinjections), and session duration usually ranges from 15 to 30 minutes.

Solution composition varies widely between practitioners — there is no formal standardization. Frequent combinations include lidocaine or procaine (as anesthetic vehicle), nonsteroidal anti-inflammatory drugs at low concentrations, vasodilators such as pentoxifylline, and occasionally B-complex vitamins. The choice of each component should be justified case by case and discussed with the patient; in practice, many formulations follow school protocols, without documented personalization.

The typical protocol involves 4 to 6 weekly sessions, with reassessment after the initial series. Transient local reactions — erythema, mild edema, tenderness at insertion points — are frequent and expected in the first 24-48 hours. If at the end of the 4-6 sessions there is no clinically relevant improvement (reduction of at least 30% on the pain scale, observable functional gain, reduction of analgesics), continuation is usually not justifiable, and other modalities with better evidence should be resumed or initiated.

Risks, adverse effects, and contraindications

When performed by a physician in an adequate setting and with sterile materials, mesotherapy has a predominantly local safety profile. Contraindications and adverse effects deserve particular attention because the technique — in non-medical contexts or with solutions of untraceable origin — has been linked in the literature to documented outbreaks of severe infection. Procedure safety depends entirely on the practitioner's qualifications and the traceability of supplies.

Common adverse effects (5-10%): transient local reactions (erythema, mild edema, tenderness), small hematomas at insertion points, momentary burning sensation during application. These manifestations are self-limited and regress within 24-72 hours in most cases.

Rare but documented risk: local bacterial infection, including cases caused by Mycobacterium abscessus and other atypical mycobacteria, reported in the literature in non-medical contexts or associated with contaminated solutions. These infections may evolve with cold abscesses, fistulas, unsightly scars, and require prolonged treatment with specific antimicrobials. The risk is virtually nonexistent when the technique is applied in a qualified medical setting, with sterile supplies, solutions prepared from a traceable source, and rigorous aseptic technique.

Important statement: the application of mesotherapy must be strictly restricted to a medical setting, with sterile material, solutions prepared under medical prescription, and appropriate sanitary control. Performance by individuals without medical training, with untraceable formulations, or in environments without sanitary infrastructure is a recognized risk factor for serious complications and should not be tolerated.

Limitations and what is still not known

The limitations of mesotherapy in pain are not minor details — they form the central axis of an honest clinical decision. The main ones follow. This section deserves careful reading because appropriate use of the technique depends, above all, on understanding what it has not yet been able to demonstrate.

Central Gaps

Massive heterogeneity of protocols. No recognized standardization exists for solution composition, volume per point, number of points per session, interval between sessions, or patient selection criteria. This heterogeneity blocks robust meta-analyses and makes replication of individual study results problematic.

Scarce mechanistic data in humans. Most mechanistic explanations are drawn by analogy with other techniques (acupuncture, trigger point injection, blocks) or from sparse preclinical studies. Translational trials specific to mesotherapy in pain, with adequate biomarkers, are rare.

Regulatory considerations. Drug regulatory agencies in many countries restrict certain pharmacologic combinations in mesotherapy, especially in aesthetic contexts, and there is ongoing technical debate about off-label use of certain anesthetics and other drugs in intradermal applications. The physician\'s technical responsibility includes knowing local restrictions and ensuring regulatory compliance of the formulation used.

Absence of a specific Cochrane review. Unlike other pain modalities, mesotherapy has no formal Cochrane systematic review dedicated to the topic. That absence is, in itself, a meaningful indicator of the technique\'s marginal position in evidence-based medicine.

High out-of-pocket cost with uncertain benefit. Mesotherapy sessions are rarely covered by health insurance plans or public health systems. Per-session prices are comparable to other injectable modalities, and the full series can represent a significant out-of-pocket investment for the patient — often directed at a technique whose benefit has not been robustly demonstrated. This imbalance between certain cost and uncertain benefit is part of the clinical decision.

Relationship with medical acupuncture

Mesotherapy and medical acupuncture share some hypothetical mechanisms — both involve stimulation of cutaneous nerve endings and local neural modulation, and both can mobilize segmental reflex components. However, medical acupuncture accumulates a consistently larger volume of evidence: meta-analyses and systematic reviews available in chronic low back pain, tension-type headache, and migraine, with recommendation in relevant international guidelines — a position that mesotherapy has not reached.

To date, no RCTs directly compare mesotherapy and medical acupuncture or evaluate the combination of the two techniques in controlled series. In clinical practice, this gap in comparative data matters for sequencing decisions: I prefer to sequence the modalities (acupuncture first, given its more solid evidence base, and consider mesotherapy only if the response is insufficient and the other alternatives also do not produce benefit) rather than combining them in the same session. Simultaneous combination tends to offer uncertain added value, with potential overlap of hypothetical mechanisms and difficulty in attributing the effect to one component or the other.

When to seek medical help

Evaluating mesotherapy as a therapeutic option starts with a structured medical assessment of chronic pain. Given the current level of evidence, consider mesotherapy only after discussing all better-supported alternatives — and after trying those that make sense for your specific case. Seeking an injectable procedure should not be the first response to persistent pain.